Luo J, Wang X, Yang Y, Mao Q (2015) Role of micro-RNA (miRNA) in pathogenesis of glioblastoma. Eur Rev Med Pharmacol Sci 19:1630–1639

CAS  PubMed  Google Scholar 

Morokoff A, Jones J, Nguyen H, Ma C, Lasocki A, Gaillard F, Bennett I, Luwor R, Stylli S, Paradiso L (2020) Serum MicroRNA is a biomarker for post-operative monitoring in glioma. J Neurooncol 149:391–400

Article  CAS  PubMed  Google Scholar 

Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP, Romani M (2017) MicroRNA in glioblastoma: an overview. International Journal of Genomics 2017

Batool SM, Hsia T, Khanna SK, Gamblin AS, Rosenfeld Y, You DG, Carter BS, Balaj L (2022) Decoding vesicle-based precision oncology in gliomas. Neuro-Oncology Adv 4:ii53–ii60

Article  Google Scholar 

He J, Jiang Y, Liu L, Zuo Z, Zeng C (2021) Circulating MicroRNAs as promising diagnostic biomarkers for patients with glioma: a meta-analysis. Front Neurol 11:610163

Article  PubMed  PubMed Central  Google Scholar 

Qu S, Guan J, Liu Y (2015) Identification of MicroRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J Neurol Sci 348:181–187

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906

Article  PubMed  Google Scholar 

Chou C-H, Chang N-W, Shrestha S, Hsu S-D, Lin Y-L, Lee W-H, Yang C-D, Hong H-C, Wei T-Y, Tu S-J (2016) MiRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44:D239–D247

Article  CAS  PubMed  Google Scholar 

Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk–database: prediction of possible MiRNA binding sites by walking the genes of three genomes. J Biomed Inform 44:839–847

Article  CAS  PubMed  Google Scholar 

Clarke DJ, Jeon M, Stein DJ, Moiseyev N, Kropiwnicki E, Dai C, Xie Z, Wojciechowicz ML, Litz S, Hom J (2021) Appyters: turning Jupyter notebooks into data-driven web apps. Patterns 2:100213

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10:1523. https://doi.org/10.1038/s41467-019-09234-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Li X, Li W, Zheng H (2015) miR-130a can predict response to Temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. J Transl Med 13:69. https://doi.org/10.1186/s12967-015-0435-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A (2015) A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget 6:29285–29295. https://doi.org/10.18632/oncotarget.4978

Article  PubMed  PubMed Central  Google Scholar 

Haemmig S, Baumgartner U, Glück A, Zbinden S, Tschan MP, Kappeler A, Mariani L, Vajtai I, Vassella E (2014) miR-125b controls apoptosis and Temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Cell Death Dis 5:e1279. https://doi.org/10.1038/cddis.2014.245

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, Westhead D, Alder JE, Shaw L, Short SC, Lawler SE (2015) Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol 9:704–714. https://doi.org/10.1016/j.molonc.2014.11.004

Article  CAS  PubMed  Google Scholar 

Ho KH, Cheng CH, Chou CM, Chen PH, Liu AJ, Lin CW, Shih CM, Chen KC (2019) miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances Temozolomide cytotoxicity in glioblastoma multiforme. Pharmacol Res 147:104390. https://doi.org/10.1016/j.phrs.2019.104390

Article  CAS  PubMed  Google Scholar 

Hui-Yuan C, Wen-Bin L, Chuan-Bao Z, Wei Z, Hu-Yong Z (2014) miR-629-3p level significantly predicts prognosis in glioblastoma patients treated with Temozolomide chemotherapy. Curr Signal Transduct Ther 9:9–14. https://doi.org/10.2174/1574362409999140707103609

Article  CAS  Google Scholar 

Kang EM, Yin AA, He YL, Chen WJ, Etcheverry A, Aubry M, Barnholtz-Sloan J, Mosser J, Zhang W, Zhang X (2019) A five-CpG signature of MicroRNA methylation in non-G-CIMP glioblastoma. CNS Neurosci Ther 25:937–950. https://doi.org/10.1111/cns.13133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matos B, Bostjancic E, Matjasic A, Popovic M, Glavac D (2018) Dynamic expression of 11 MiRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status. Radiol Oncol 52:422–432. https://doi.org/10.2478/raon-2018-0043

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (2012) MiR-181d: predictive glioblastoma biomarker that downregulates MGMT expression. Neurooncology 14:712–719. https://doi.org/10.1093/neuonc/nos089

Article  CAS  Google Scholar 

Li DM, Chen QD, Wei GN, Wei J, Yin JX, He JH, Ge X, Shi ZM (2020) Hypoxia-Induced miR-137 Inhibition increased glioblastoma multiforme growth and chemoresistance through LRP6. Front Oncol 10:611699. https://doi.org/10.3389/fonc.2020.611699

Article  PubMed  Google Scholar 

Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D, Vyzula R, Michalek J (2010) MicroRNA-181 family predicts response to concomitant chemoradiotherapy with Temozolomide in glioblastoma patients. Neoplasma 57:264–269. https://doi.org/10.4149/neo_2010_03_264

Article  CAS  PubMed  Google Scholar 

Yan W, Liu Y, Yang P, Wang Z, You Y, Jiang T (2015) MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. Oncotarget 6:11676–11682. https://doi.org/10.18632/oncotarget.3258

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Liu Q, Guan Y, Li Z, Wang Y, Liu Y, Cui R (2019) MiR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway. J Experimental Clin Cancer Res 38. https://doi.org/10.1186/s13046-019-1370-1

Niyazi M, Pitea A, Mittelbronn M, Steinbach J, Sticht C, Zehentmayr F, Piehlmaier D, Zitzelsberger H, Ganswindt U, Rödel C, Lauber K, Belka C, Unger K (2016) A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget 7:45764–45775. https://doi.org/10.18632/oncotarget.9945

Article  PubMed  PubMed Central  Google Scholar 

Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR (2013) Correlation of MicroRNA 132 Up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant Temozolomide chemotherapy. Transl Oncol 6:742–748. https://doi.org/10.1593/tlo.13553

Article  PubMed  PubMed Central  Google Scholar 

Wang H, Wu B, Wang J, Hu Y, Dai X, Ye L, Cheng H (2021) Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with Temozolomide. Clin Neurol Neurosurg 200:106344. https://doi.org/10.1016/j.clineuro.2020.106344

Article  PubMed  Google Scholar 

Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T (2013) Whole-genome MicroRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119:814–824. https://doi.org/10.1002/cncr.27826

Article  CAS  PubMed  Google Scholar 

Swellam M, Bakr NM, El Magdoub HM, Hamza MS, Ezz El Arab LR (2021) Emerging role of MiRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. J Mol Neurosci 71:836–844

Article  CAS  PubMed  Google Scholar 

Wang J, Li T, Wang B (2021) Exosomal transfer of miR-25-3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. Int J Oncol 59. https://doi.org/10.3892/ijo.2021.5244